AbCellera Biologics Inc. ABCL
11.02 USD -0.01 (-0.09%)
Regular-session close
11.17 +0.15 +1.36%
After hours · Nov 18, 7:39 PM ET
10.96 Day range 11.55
2.75 52-week range 15.02
- YTD
- +222.22%
- 1 year
- +201.09%
News
seekingalpha.com AbCellera Biologics Inc. (ABCL) Presents at UBS Global Biopharma Conference 2026 Transcript AbCellera Biologics Inc. (ABCL) Presents at UBS Global Biopharma Conference 2026 Transcript
marketbeat.com AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot flash treatment ABCL635 into late-stage studies, with a registrational trial potentially starting around the middle of…benzinga.com Piper Sandler Maintains Overweight on AbCellera Biologics, Raises Price Target to $20 Piper Sandler analyst Allison Bratzel maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $12 to $20.
seekingalpha.com AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript AbCellera Biologics Inc. ( ABCL ) Stifel 2026 Healthcare Conference 2026 November 10, 2026 7:00 PM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Conference Call Participants…
zacks.com Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? Here is how AbCellera Biologics Inc. (ABCL) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
marketbeat.com AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot-flash treatment ABCL635 into late-stage development next year after a midstage study produced stronger-than-expected…benzinga.com StoneX Maintains Buy on AbCellera Biologics, Raises Price Target to $15 StoneX analyst Robert Wasserman maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $11 to $15.
benzinga.com Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $14 Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $9 to $14.
seekingalpha.com AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript
marketbeat.com What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call AbCellera Biologics NASDAQ: ABCL plans to advance its experimental hot flash treatment ABCL635 into late-stage development in 2027 after reporting positive mid-stage results, while shelving further…
zacks.com AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.19 per share a year ago.
benzinga.com AbCellera Biologics Q3 2026 Earnings Call Transcript AbCellera Biologics (NASDAQ:ABCL) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…benzinga.com AbCellera Biologics Q3 EPS $(0.13) Beats $(0.16) Estimate, Sales $10.639M Beat $8.416M Estimate AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 31.58 percent increase over losses of…
businesswire.com AbCellera Reports Q3 2026 Business Results VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2026 Business Results.
businesswire.com AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.
businesswire.com AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.
defenseworld.net AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Moderate Buy” from Analysts AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, Marketbeat Ratings…
zacks.com ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
businesswire.com AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
businesswire.com AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026 VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.
defenseworld.net BlackRock Inc. Makes New Investment in AbCellera Biologics Inc. $ABCL BlackRock Inc. purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ: ABCL) during the second quarter, according to the company in its most recent disclosure with the Securities and…
benzinga.com What'sGoing On With AbCellera Biologics Stock On Tuesday? AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.
seekingalpha.com Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO…
businesswire.com AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
benzinga.com What's Going on With AbCellera Biologics Stock On Wednesday? AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at…
